Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer

被引：0
|
作者：
Groener, Daniel [1 ]
Baumgarten, Justus [1 ]
Davis, Karen [1 ]
Happel, Christian [1 ]
Ngoc, Christina Nguyen [1 ]
Wichert, Jennifer [1 ]
Mader, Nicolai [1 ]
Mandel, Philipp [2 ]
Nikolaos, Tselis [3 ]
Gruenwald, Frank [1 ]
Sabet, Amir [1 ]
机构：
[1] Univ Hosp Frankfurt, Nucl Med, Frankfurt, Germany
[2] Univ Hosp Frankfurt, Urol, Frankfurt, Germany
[3] Univ Hosp Frankfurt, Radiat Oncol, Frankfurt, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
594
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Myelotoxicity after Treatment with 177Lu-PSMA-617 in Patients with Metastatic Prostate Cancer
    Groener, D.
    Baumgarten, J.
    Davis, K.
    Happel, C.
    Mader, N.
    Ngoc, C. Nguyen
    Wichert, J.
    Mandel, P.
    Tselis, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S694 - S695
  • [22] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Gaertner, Florian C.
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Hauser, Stefan
    Feldmann, Georg
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 312 - 319
  • [23] Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Becker, Anja
    Eppard, Elisabeth
    Kuerpig, Stefan
    Fisang, Christian
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [24] 177Lu-PSMA-617 for metastatic prostate cancer in India
    Ghose, Aruni
    Banerjee, Soirindhri
    Choudhury, Partha S.
    Maniam, Akash
    Gupta, Manoj
    Banna, Giuseppe L.
    Vasdev, Nikhil
    Ghose, Amit
    Noronha, Vanita
    Mitra, Swarupa
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
  • [25] Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients
    Ashfaq, Wardah
    Rehman, Khurram
    Shahid, Abubaker
    Younis, Muhammad Numair
    MEDICAL ONCOLOGY, 2024, 41 (09)
  • [26] 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) : 1579 - 1586
  • [27] Radiobiological parameters for the assessment of 177Lu-PSMA-617 Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Hu, J.
    Xue, S.
    Mercolli, L.
    Sari, H.
    Rominger, A.
    Afshar-Oromieh, A.
    Shi, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S636 - S636
  • [28] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [29] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [30] 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney
    Zhang, Jingjing
    Kulkarni, Harshad
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
12345